Wall Street analysts expect that Allogene Therapeutics Inc (NASDAQ:ALLO) will announce earnings per share (EPS) of ($0.47) for the current fiscal quarter, according to Zacks Investment Research. Zero analysts have provided estimates for Allogene Therapeutics’ earnings, with the lowest EPS estimate coming in at ($0.54) and the highest estimate coming in at ($0.37). The business is scheduled to report its next quarterly earnings report on Tuesday, August 6th.
On average, analysts expect that Allogene Therapeutics will report full-year earnings of ($1.94) per share for the current year, with EPS estimates ranging from ($2.10) to ($1.45). For the next financial year, analysts forecast that the company will post earnings of ($2.37) per share, with EPS estimates ranging from ($2.89) to ($1.71). Zacks’ earnings per share averages are an average based on a survey of sell-side research analysts that follow Allogene Therapeutics.
Allogene Therapeutics (NASDAQ:ALLO) last announced its quarterly earnings results on Tuesday, May 7th. The company reported ($0.32) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.40) by $0.08.
NASDAQ ALLO traded down $0.21 during trading on Friday, reaching $26.40. 320,634 shares of the company’s stock were exchanged, compared to its average volume of 517,616. The firm’s 50 day simple moving average is $26.99. The firm has a market capitalization of $3.23 billion and a PE ratio of -4.01. The company has a quick ratio of 17.48, a current ratio of 17.48 and a debt-to-equity ratio of 0.05. Allogene Therapeutics has a fifty-two week low of $21.67 and a fifty-two week high of $35.55.
In other news, insider Alison Moore sold 48,828 shares of the company’s stock in a transaction on Monday, June 3rd. The shares were sold at an average price of $26.76, for a total transaction of $1,306,637.28. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, major shareholder Group Holdings (Sbs) Advis Tpg sold 1,918,755 shares of the company’s stock in a transaction on Tuesday, May 14th. The stock was sold at an average price of $29.38, for a total transaction of $56,373,021.90. The disclosure for this sale can be found here. 36.50% of the stock is currently owned by corporate insiders.
Several large investors have recently made changes to their positions in ALLO. Rhumbline Advisers acquired a new position in Allogene Therapeutics during the 4th quarter worth $829,000. First Trust Advisors LP acquired a new position in Allogene Therapeutics during the 4th quarter worth $2,732,000. BlackRock Inc. acquired a new position in Allogene Therapeutics during the 4th quarter worth $56,011,000. Bank of New York Mellon Corp acquired a new position in Allogene Therapeutics during the 4th quarter worth $941,000. Finally, Raymond James & Associates acquired a new position in Allogene Therapeutics during the 4th quarter worth $673,000. Institutional investors own 53.47% of the company’s stock.
About Allogene Therapeutics
Allogene Therapeutics, Inc, a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer. The company is developing UCART19, an allogeneic chimeric antigen receptor (CAR) T cell product candidate, which is in Phase I clinical trials for the treatment of pediatric and adult patients with R/R CD19 positive B-cell ALL; and ALLO-501, an allogeneic CAR T cell product candidate targeting CD19 to treat R/R non-Hodgkin lymphoma.
Featured Story: Cost of Equity For A Business, Investors
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Allogene Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Allogene Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.